Is the serum level of survivin, an antiapoptotic protein, a potential predictive and prognostic biomarker in metastatic pancreatic cancer?

Basit Öğe Kaydı
dc.authoridCavdar, Eyyup/0000-0001-5885-3047
dc.authoridYOLCU, AHMET/0000-0002-4525-2020
dc.contributor.authorDemirci, Nebi Serkan
dc.contributor.authorCavdar, Eyyup
dc.contributor.authorErdem, Gokmen Umut
dc.contributor.authorHatipoglu, Engin
dc.contributor.authorCelik, Emir
dc.contributor.authorSezer, Sevilay
dc.contributor.authorYolcu, Ahmet
dc.date.accessioned2024-10-29T17:58:40Z
dc.date.available2024-10-29T17:58:40Z
dc.date.issued2023
dc.departmentTekirdağ Namık Kemal Üniversitesi
dc.description.abstractIn the present study, we aimed to assess the association between the serum survivin level and overall survival and treatment response rates in metastatic pancreatic cancer (MPC). Serum samples were prospectively collected from 41 patients with newly diagnosed MPC patients and 41 healthy individuals (control group) to assess the survivin levels. The median survivin level was 136.2ng/mL in patients with MPC and 52ng/mL in healthy individuals (P = .028). Patients were divided into low- and high-survivin groups according to the baseline median survivin level. Patients with a high serum survivin level compared with a low serum survivin level had shorter median progression-free survival (2.39 vs 7.06 months; P = .008, respectively) and overall survival (3.74 vs 9.52 months; P = .026, respectively). Patients with higher serum survivin levels had significantly worse response rates (P = .007). The baseline high level of serum survivin in patients with MPC may be associated with treatment resistance and poor prognosis. A confirmation will be needed for these results in future large multicenter prospective studies.
dc.identifier.doi10.1097/MD.0000000000034014
dc.identifier.issn0025-7974
dc.identifier.issn1536-5964
dc.identifier.issue25en_US
dc.identifier.pmid37352081
dc.identifier.scopus2-s2.0-85162790662
dc.identifier.scopusqualityQ3
dc.identifier.urihttps://doi.org/10.1097/MD.0000000000034014
dc.identifier.urihttps://hdl.handle.net/20.500.11776/14440
dc.identifier.volume102
dc.identifier.wosWOS:001053308900062
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherLippincott Williams & Wilkins
dc.relation.ispartofMedicine
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectpancreatic cancer
dc.subjectsurvival
dc.subjectsurvivin
dc.titleIs the serum level of survivin, an antiapoptotic protein, a potential predictive and prognostic biomarker in metastatic pancreatic cancer?
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu